The global burden of diabetic foot disease, The Lancet, vol.366, issue.9498, pp.1719-1743, 2005. ,
DOI : 10.1016/S0140-6736(05)67698-2
Preventive Foot Care in People With Diabetes, Diabetes Care, vol.21, issue.12, pp.2161-77, 1998. ,
DOI : 10.2337/diacare.21.12.2161
Diagnosis and Treatment of Diabetic Foot Infections, Clinical Infectious Diseases, vol.39, issue.7, pp.885-910, 2004. ,
DOI : 10.1086/424846
Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem, Diabetic Medicine, vol.3, issue.2, pp.159-61, 2003. ,
DOI : 10.1046/j.1464-5491.2001.00590-5.x
MRSA and osteomyelitis of the foot in diabetes, Diabetic Medicine, vol.20, issue.s4, pp.16-25, 2004. ,
DOI : 10.1055/s-2001-18655
Principles and practice of antibiotic therapy of diabetic foot infections, Diabetes/Metabolism Research and Reviews, vol.16, issue.S1, pp.42-48, 2000. ,
DOI : 10.1002/1520-7560(200009/10)16:1+<::AID-DMRR109>3.3.CO;2-2
Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers, Clinical Microbiology and Infection, vol.12, issue.2, pp.186-195, 2006. ,
DOI : 10.1111/j.1469-0691.2005.01279.x
Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic, Diabetic Medicine, vol.37, issue.9, pp.767-71, 1999. ,
DOI : 10.1002/(SICI)1096-9136(199602)13:2<156::AID-DIA59>3.0.CO;2-U
A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia, Clinical Therapeutics, vol.24, issue.11, pp.1770-85, 2002. ,
DOI : 10.1016/S0149-2918(02)80078-9
Ertapenem: a new carbapenem, Expert Opinion on Investigational Drugs, vol.42, issue.6, pp.1157-66, 2001. ,
DOI : 10.2165/00003088-200039030-00002
Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial, The Lancet, vol.366, issue.9498, pp.1695-703, 2005. ,
DOI : 10.1016/S0140-6736(05)67694-5
Validation of the Infectious Diseases Society of America's Diabetic Foot Infection Classification System, Clinical Infectious Diseases, vol.44, issue.4, pp.562-567, 2007. ,
DOI : 10.1086/511036
In Vitro Activities of Ertapenem (MK-0826) against Recent Clinical Bacteria Collected in Europe and Australia, Antimicrobial Agents and Chemotherapy, vol.45, issue.6, pp.1860-1867, 2001. ,
DOI : 10.1128/AAC.45.6.1860-1867.2001
Use of the E-test for determining antimicrobial susceptibility of anaerobic bacteria, Pathol Biol, vol.44, pp.358-62, 1996. ,
Antibiotic Susceptibility Testing Committee of the French Society for Microbiology, 2007. ,
Extended Broad-Spectrum ??-Lactamases Conferring Transferable Resistance to Newer ??-Lactam Agents in Enterobacteriaceae: Hospital Prevalence and Susceptibility Patterns, Clinical Infectious Diseases, vol.10, issue.4, pp.867-78, 1988. ,
DOI : 10.1093/clinids/10.4.867
Microbiological profile of infected diabetic foot ulcers, Diabet Med, vol.19, pp.1032-1037, 2002. ,
Bacterial etiology of diabetic foot infections in South India, European Journal of Internal Medicine, vol.16, issue.8, pp.567-70, 2005. ,
DOI : 10.1016/j.ejim.2005.06.016
Diabetic Foot Infections: Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases, Diabetes Care, vol.19, issue.6, pp.638-679, 1996. ,
DOI : 10.2337/diacare.19.6.638
Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact, Diabetic Medicine, vol.106, issue.7, pp.710-715, 2004. ,
DOI : 10.1111/j.1464-5491.2004.01237.x